PDL Biopharma PEG Ratio

The latest PEG ratio for PDLI is -0.0. That is above the Healthcare sector average of -5.81. Investors often review this figure alongside PDL Biopharma's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, PDLI currently prints -0.0 for PEG ratio, while the sector average sits near -5.81. That is roughly 100.0% above the sector mean. Large gaps often invite a closer look at PDL Biopharma's growth, margins, and balance sheet.

A PEG ratio of -0.0 for PDL Biopharma is not 'good' or 'bad' on its own. Compare it with the peer average (-5.81) and with PDLI's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting PDLI's PEG ratio (-0.0), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack PDL Biopharma's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.